BMT/Oncologist & Associate CMO @StephensonCC | Assoc Professor of Medicine @UofOklahoma I Alumni @MDAndersonnews @VCUMassey | #CORDS lab, posts = my opinions
Oklahoma City, OK
- Tweets 2,367
- Following 943
- Followers 1,480
- Likes 7,818
Pinned Tweet
Interrupting my usual #MedTwitter posts to mark 3.11.2023 as best day of my life ❤️
72
11
798
84,798
Incredible results !
#IMS26 #pietersonneveld presenting 6-yr (!) follow-up for PERSEUS.
In standard-risk myeloma, 6-year PFS 88% 🤩
For HR cytogenetics, adding dara basically converts into standard-risk prognosis.
Great, but we need to do better: BsAbs or CAR-T will be the way to close this gap.
1
264
A new great option for patients , expecting approval in the near future #CARtcell
A meaningful milestone for Arlo-cel (GPRC5D CAR for myeloma): Registration phase II top line results reported. One step closer toward potential approval and bringing a new treatment option for patients. news.bms.com/news/details/20… #MMsm
3
467
I’m very proud of our @OUCollegeofMed 🌟M2 student Trent Gibson presenting his #CARtcell work at #SOHO2026 .. we’re fortunate here at @StephensonCC to have motivated hard working trainees (also future oncologists)
1
11
636
Great to finally meet Dr. Siddhartha Mukherjee at the OU Presidential Speakers Dinner. A fascinating conversation on AI, cancer research, and where oncology is headed next. Always inspiring to hear from someone who has helped shape how so many of us think about cancer @OUHealth
1
14
640
Grateful for this recognition from my colleagues at @OUCollegeofMed Academy of Teaching Scholars. Teaching, mentoring, and learning alongside our students & trainees is a privilege that I truly cherish.
5
2
39
2,033
Thank you Dr. @VincentRK for an outstanding @StephensonCC Hematology Oncology Grand Rounds on Past, Present and Future of Monoclonal Gammopathy & Smoldering Multiple Myeloma. The trajectory of these fields look so promising !
3
3
16
6,335
AlloHCT remains a curative therapy for high risk relapsed refractory CLL/SLL #bmtsm
High-risk single-refractory and double-refractory chronic lymphocytic leukemia: feasibility and impact of alloHCT ashpublications.org/bloodadv…
1
9
1,018
Thank you @DAVAOnc for the opportunity to present our work. High dose chemotherapy and autologous stem cell rescue is associated with durable response in this aggressive malignancy #bmtsm #lymsm
Role of HCT in PlasmablasticLymphoma: Dr. Taha Al-Juhaishi(@Taha_CancerDoc, @UofOklahoma) presents a CIBMTR analysis of HCT (autoHCTn=186, alloHCTn=31): both give durable survival, especially autoHCT after first line (3-year PFS 75%). #DAVAHeme
3
7
1,098
Thank you @DAVAOnc for the opportunity to present on one of my new favorite topics .. CAR-T cell therapy in Autoimmune Diseases especially SLE #CARtcell #Cell_Therapy
Dr. Taha Al-Juhaishi (@Taha_CancerDoc) (@UofOklahoma) highlights the role of CD19 CAR-T in refractory ADs. In the Phase I/II CASTLE trial, 87.5% (7/8) of patients responded, all discontinued glucocorticoids and other immunosuppressive therapies. Across early clinical studies, CAR-T induced durable drug-free remissions with predominantly grade 1–2 CRS and no ICANS. #DAVAHeme
4
9
1,493
Critical message on how to deliver an effective talk , all these recommendations should be core requirements
Being able to deliver a great talk/presentation is really important for academic success. Especially in medicine.
1) Know your audience: If it’s clinicians, keep your talk relevant. You don’t need to impress them with all that you know about complex mechanism of action pathways, unavailable genomic tests, and a lot of phase I investigational stuff.
2) Razor focus on the title of the talk: Easy concept but one is see even experts miss. If the talk is on how you treat, tell them how you treat. Don’t spend half the time on pathogenesis or the latest research in your lab.
3) Keep slides simple: I often see entire posters on a single slide. It’s better to show one summary figure or a simple table and keep the audience engaged with your voice and explanation
4) Clarity: An essential ingredient. speak into the mic. Be crystal clear; Build up the story so even someone not in your field will be able to follow along.
5) Know your subject extremely well: The most important of all. You cannot do 1-4 without this. Being complex is easy. Simple is hard. Simple comes only with a really strong command of the subject and the data.
Plan your opening and ending. Rest has to be conversational and not reading off the slides. Takes time and practice.
Chime in if you have other thoughts or ideas.
3
941
Taha A, MD, MBA retweeted
Tagraxofusp, Azacitidine, and Venetoclax in Blastic Plasmacytoid Dendritic Cell Neoplasm ashpublications.org/blood/ar… | #BPDCN #endcancer @lane_andy @LuskinMarlise @ShaiShimony @NitinJainMD @Daver_Leukemia @mkonople @doctorpemm || @BloodPortfolio || @bcutd_research @VJHemOnc @TheIACH
9
33
1,708
A milestone in our Transplant field, first approval of a modified Allogeneic graft @OrcaBio
Check out my previous @ASTCT podcast with Dr. @LoriMuffly from @StanfordMed where we discuss the current evidence and future of this therapy #bmtsm
podcasts.apple.com/us/podcas…
1
1
10
936
Happy Father’s Day to all the dads — especially the girl dads!
Started the day with a mini celebration from my favorite little boss, now off to @OUHealth @StephensonCC to round on our BMT & Cell Therapy patients. Grateful heart today.
1
19
929
I support David’s conclusion. Majority of patients with large B-cell lymphoma should no longer get HDMTX for CNS prophy and definitely not intercalated with their essential first line regimen
Hope we can get payer coverage for ctDNA testing on CSF soon #lymsm
My impression of the cumulative data:
CNS prophylaxis is only warranted when following a specific protocol. Burkitts regimens (EPOCH or modified Magrath)? Check. DHL regimens (EPOCH or HyperCVAD)? Testicular regimens (IELSG10/30)? Check.
Run of the mill DLBCL strategies? Nope, irrespective of CNS-IPI. But make sure to use pola-R-CHP for non-GCB!
1
3
480
Taha A, MD, MBA retweeted
#EHA2026 #AML #leusm
Dr. Barote: OPTI-AML: the first prospective RCT of Ven 14d vs 28d + Aza ×2 cycles in older AML — and it reframes the whole “shorter is fine” debate.
AV14 did NOT meet non-inferiority for CR (43% vs 49% AV28; ΔCI –8% to +21%, upper bound >10%).
Key takeaways 👇🏽
But the real story is molecular, not calendar:
• NPM1 & IDH1/2 → favored 28d (61% vs 42%)
• Every other subset → 44% vs 44%, identical
And cumulative delivery, not the planned schedule, tracked with response: pts who couldn’t complete Ven had lower CR in BOTH arms (AV28 39% vs 56%; AV14 36% vs 49%). Only 68% of AV28 finished C1 Ven (vs 89%) — mostly infections.
MRD negativity (78% vs 77%) and toxicity were superimposable. OS numerically favored AV28 but on MVA was driven by TP53/KRAS + counts, not arm.
Bottom line: Ven duration should be titrated to molecular subtype + triplet partner — what matters is cumulative exposure delivered, and for NPM1/IDH that exposure still earns its keep. #EHA2026 #EHA26
19
39
2,452
As #celltherapy physicians it is critical we expand our practice and programs to include these novel therapies in more aggressive diseases with high unmet need . My clinic now has autoimmune , melanoma (getting CARs and TILs) and hopefully others in the near future #ASCO25
7
805
Our @OUdoim @StephensonCC current and former fellows are ⭐️s @Noha_Soror is a #CARtcell research mentor to so many fellows residents and students here
With the amazing @Noha_Soror who continues to make a difference - winner of the “Most Engaged Working Group” award.
KUDOS my friend and well deserved.
@ASCO #ASCO26
1
3
10
760
Excited to share our new publication in @ASTCT_Journal :
astctjournal.org/article/S26…
Plasmablastic lymphoma is a rare, highly aggressive lymphoma with limited prospective data and no clearly established optimal consolidation strategy.
1/
2
2
16
2,054
Rare cancers require large collaborations and registry-based efforts to move the field forward. I am deeply grateful to my mentors and senior coauthors @MediHumdani and Dr. Sairah Ahmed for their leadership and support 4/
1
1
106
I’m also thankful to all collaborators involved in this work from @CIBMTR @ASTCT
#PlasmablasticLymphoma #Lymphoma #StemCellTransplant #AutoHCT #AlloHCT #CellularTherapy #Transplantation #RareCancers
1
1
127